for identifying patients at risk of developing AKI we studied a cohort with nine broad classification of disease who did not have AKI. Details regarding the population that was targeted for inclusion in the study are also described. Finally, we present data on the inclusion criteria for the healthy subjects used in this investigation to determine the reference range.
. In order to determine the specificity of [IGFBP7] Á [TIMP -2] for identifying patients at risk of developing AKI we studied a cohort with nine broad classification of disease who did not have AKI. Details regarding the population that was targeted for inclusion in the study are also described. Finally, we present data on the inclusion criteria for the healthy subjects used in this investigation to determine the reference range.
& 
Value of the data
The data described allow other researchers to understand the patient cohort we used to determine the specificity of the AKI biomarkers [IGFBP7] Á [TIMP-2] in the setting of stable chronic comorbid conditions.
We included patients with cardiovascular, respiratory, gastrointestinal, renal, muscular skeletal, endocrine, and neuromuscular disease in the stable chronic comorbid condition cohort who did not have AKI, which serves as a model for future studies.
We describe inclusion criteria for a healthy reference range population that can also be used for future studies evaluating biomarkers of AKI.
Data
The data described provide details on the conditions and numbers of subjects evaluated who did not have AKI but did have other chronic stable comorbid conditions that were used to demonstrate the specificity of these biomarkers for AKI. We also describe the targeted patient population and the inclusion criteria that were used to determine the reference range of [IGFBP7] Á [TIMP-2] in healthy individuals.
Experimental design, materials and methods
The reference range study was designed to include patients commonly seen in intensive care units of hospitals in the United States [2] . The list of patients with chronic stable comorbid conditions is presented in Table 1 . Table 2 gives a description of patient demographics that were targeted for inclusion. Table 3 provides detailed inclusion criteria used to select the healthy reference range population.
The protocols for this investigation were approved by investigational review boards/ethics committees as required by each participating institution. All subjects provided written informed consent. Subjects of Z21 years age, who provided written informed consent for the study participation, and met the morbidity criteria (Table 1) were selected in the stable chronic morbidity cohort. For apparently healthy subjects, individuals of Z21 years of age, who provided written informed consent for study participation, and met the healthy criteria (Table 2) , were selected for this cohort. The patients were recruited at 6 geographically diverse sites (Rochester, NY; Dallas, TX; Gresham, OR; Springfield, MO; Layton, UT; Peoria, AZ). In the stable chronic comorbid cohort most patients had several comorbidities, with the most prevalent being some type of an endocrine or cardiovascular disorder. In terms of specific comorbidities, as might be expected for the US population, the highest prevalence was hypertension (59.7%) with the other top four being hypercholesterolemia (40.1%), osteoarthritis (28.8%), and diabetes (24.5%).
